Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for China SXT Pharmaceuticals, Inc. (SXTC:NASDAQ), powered by AI.
China SXT Pharmaceuticals, Inc. is currently trading at $2.57. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for China SXT Pharmaceuticals, Inc. on Alpha Lenz.
China SXT Pharmaceuticals, Inc.'s P/E ratio is -0.0.
“China SXT Pharmaceuticals, Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -22.5%.”
Ask for details →China SXT Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on the development, production, and sale of Chinese traditional medicine products. The company primarily engages in the creation of Advanced and Directly-Oral Solutions of Traditional Chinese Medicine Pieces (TCMPs) and Fine TCMPs, aiming to modernize and enhance the accessibility of traditional formulations. China SXT Pharmaceuticals caters to a diverse customer base, including hospitals, pharmacies, and end-consumers, by providing herbal and plant-based remedies that are deeply rooted in centuries-old Chinese medical practices. Positioned in the healthcare and pharmaceuticals sector, the company's innovations not only serve the domestic Chinese market but also seek to establish a global presence in the growing field of alternative medicine. Headquartered in Taizhou Jiangsu, China, China SXT Pharmaceuticals, Inc. plays a significant role in bridging traditional healing methods with contemporary healthcare demands, by leveraging unique, time-tested product offerings in a modern pharmaceutical context.
“China SXT Pharmaceuticals, Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -22.5%.”
Ask for details →China SXT Pharmaceuticals, Inc. (ticker: SXTC) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 75 employees. Market cap is $24,384.
The current price is $2.57 with a P/E ratio of -0.01x and P/B of 0x.
ROE is -22.50% and operating margin is -153.97%. Annual revenue is $2M.